Adora Ndu is a distinguished leader in the biopharmaceutical industry with almost 20 years of experience in drug development, regulatory affairs, and public health policy. Currently, she serves as the Chief Regulatory Officer, and Executive Vice President of Portfolio Strategy and Management at BridgeBio Pharma, Inc. (NASDAQ: BBIO), a pioneering company focused on developing transformative medicines for patients with genetic diseases and cancers. In this role, she oversees regulatory affairs, quality assurance, government affairs, and portfolio strategy and management, enabling the company's efforts to bring life-changing therapies to rare disease populations. She also previously served as BridgeBio’s interim Chief Legal Officer, where she directed the company’s legal affairs, governance, and compliance initiatives. Prior to her work at BridgeBio, Dr. Ndu was Group Vice President of Worldwide Research & Development Strategy, Scientific Collaborations, and Policy at BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global leader in developing innovative therapies for rare genetic diseases. In this capacity, she advanced BioMarin’s strategic priorities in R&D and was instrumental in guiding collaborations that expanded the company’s research capabilities. Earlier, as Vice President of Regulatory Affairs at BioMarin, she played a key role in the successful regulatory approvals of pharmaceutical products globally, directly impacting the lives of patients with rare and life-limiting conditions. Dr. Ndu has also held critical leadership roles at the U.S. Food and Drug Administration (FDA). She served as Director and Head of the Division of Medical Policy Development within the Center for Drug Evaluation and Research (CDER), where she influenced policy frameworks that have shaped drug development and regulatory standards. In previous FDA roles, including as a Commander in the U.S. Public Health Service, she regulated drug product advertising and promotion, and post-market safety, underscoring her deep commitment to public health and regulatory innovation. An esteemed thought leader in rare disease drug development, Dr. Ndu is known for her forward-thinking approaches to regulatory science and policy. She has been a strategic advisor for many organizations, has served as a speaker on numerous panels addressing critical issues in the rare disease ecosystem, and has received recognition for her contributions, including numerous awards from the U.S. Public Health Service, such as the Outstanding Service Medal, for her dedication to advancing public health. Dr. Ndu was recognized by the Maryland Daily Record as a leading woman under the age 40 for notable impact across her career and has served as the keynote speaker for the Howard University College of Pharmacy 2023 commencement ceremony. Dr. Ndu holds a Pharm.D. from Howard University’s College of Pharmacy, completed residency at Georgetown University Hospital, and trained as a medical affairs fellow at Procter & Gamble Pharmaceuticals (P&G). She holds a J.D. from the University of Maryland, adding a legal perspective to her scientific expertise. Her commitment to advancing healthcare innovation extends beyond her corporate roles; she is an active member of the community, serving on non-profit boards (Alliance for Regenerative Medicine, the Food and Drug Law Institute, Howard University College of Pharmacy), and currently serves on the Boards of Directors for Acadia Pharmaceuticals (NASDAQ: ACAD) and DBV Technologies (NASDAQ: DBVT), where her expertise supports governance and strategy in advancing patient care globally. In 2024 she was welcomed into the membership of the Economic Club of Washington DC. Dr. Ndu’s work has had a profound impact on the rare disease and biopharmaceutical landscapes, where her leadership continues to drive advancements in regulatory pathways, drug approvals, and patient-centered healthcare solutions.